Skip to content

Evaluation of Ultrasonic Electrical Transdermal Medication in Postoperative Intestinal Function Recovery: a Randomized Controlled Trial

Evaluation of Ultrasonic Electrical Transdermal Medication in Postoperative Intestinal Function Recovery: a Randomized Controlled Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17013630
Enrollment
Unknown
Registered
2017-12-01
Start date
2017-07-01
Completion date
Unknown
Last updated
2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases of elective Gastrointestinal surgery

Interventions

experimental group:In addition to routine treatment, ultrasonic electrical transdermal medication is adopted.
Control group:Preoperative preparation, Intraoperative management and postoperative treatment should comply with the principle of ERAS. The use of drugs that affects gastrointestinal motility is forbi

Sponsors

Liyong
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Schedule to undergoing laparoscopic gastrointestinal surgery; 2) Aged between 18 and 75 years; 3) Undergo general anesthesia with operation time no more than 6 hours and postoperative intravenous analgesia; 4) Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Women during pregnancy or lactation; 2) Patients of emergency surgery patients with extensive metastasis of gastrointestinal tumors or extensive adhesions in the abdominal cavity; 3) Patients with severe intra-abdominal infection; 4) Patients with acute total intestinal obstruction; 5) A colostomy or enterostomy should be performed and bowel discharge and defecation could not be assessed; 6) Patients with postoperative unstable vital signs such as ketoacidosis, hyperosmolar nonketotic coma, severe dehydration, electrolyte disorders; 7) Patients with severe cardiovascular and cerebrovascular diseases and severe primary diseases of hematopoietic system; 8) Poor glycemic control (fasting blood glucose > 8 mmol/L); 9) Liver function (ALT) > 1.5 times of upper limit of normal or kidney function (Cr) > upper limit of normal; 10) Obesity (BMI > 35) or severe malnutrition (BMI < 15); 11) A pacemaker, an artificial stent, and an artificial valve holder; 12) Severe complications or serious infection occurred on the first day after operation, or the patient was not conscious; 13) Use of drugs that affects gastrointestinal motility within one week before surgery; 14) Patients who are participating in or have ever participated in other clinical trials within 4 weeks before the study; 15) Researchers believe that some patients are not appropriate for this clinical trial.

Design outcomes

Primary

MeasureTime frame
The time of the first anus exhaust;

Secondary

MeasureTime frame
The recovery time of bowel sounds;The time of the first defecation;Gastrointestinal complications after surgery such as vomit and abdominal distension;Hospital stay and expense;

Countries

China

Contacts

Public ContactLi Yong

Gastrointestinal surgery of Guangdong General Hospital

yuan821007@126.com+86 13822177479

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026